WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Forum: Aktien User: Summer.76

WuXi AppTec (02359 HK) 56,000 shares will be listed for circulation on September 16 https://m.jrj.com.cn/madapter/hk/2021/09/10212433417126.shtml Greenway on September 10th | WuXi AppTec (02359 HK) issued an announcement regarding the company's 2018 restricted stock and stock option incentive plan to reserve stock options for the second exercise period. The number of partial exercise shares is 56,448 shares. The time for the listing and circulation of the secondary exercise stock is September 16, 2021.

Aber durchhalten und auch nachkaufen lohnt sich m.M.n. mittel- bis langfristig

Das stimmt.

Hängt ja momentan nicht an den Zahlen, sondern eher daran, was im Land passiert. Geht der WuXi Bio ähnlich. Dort im Forum hatte ich etwa Mitte August Infos eingestellt, warum (nicht nur) die Pharmatitel leiden.

Ok. Das sollte sich doch im Kurs wieder spiegeln

WuXi AppTec Reports Strong 2021 Interim Results https://finance.yahoo.com/news/wuxi-apptec-reports-strong-2021-095200729.html • Revenue Up 45.7% Year-Over-Year to RMB10,537 Million • Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million • Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 • Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-Year to RMB2,448 Million • Adjusted Non-IFRS Diluted EPS Up 58.5% Year-Over-Year to RMB0.84 ...

Major Pharmas Broadly Shorted http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.210812_111612/hk-stock-news ... WUXI APPTEC (02359 HK) and WUXI BIO (02269 HK) likewise slumped for two consecutive days, with the former dropping to as low as $155.5 at one point; last posted $156.2, down 4.5%. The latter, reaching below its 100MA at one point, lasted stood at $118.8, down 3.8%. ...

Vaccine pharmaceutical stocks fell collectively, and WuXi AppTech slumped over 9% https://news.stcn.com/sd/202108/t20210806_3516188.html

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland https://www.prnewswire.co.uk/news-releases/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland-855233922.html State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe while better enabling global customers ...

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1115772/hk-stock-news JPM: Focus on High-Quality Pharmas Post-correction, Incl. WUXI BIO, WUXI APPTEC

WuXi AppTec (02359 HK) fund shareholders intend to reduce their holdings of 29.52 million A shares https://www.finet.hk/newscenter/news_content/60ff4e5ebde0b337360b8fc8

Pharmasektor allgemein heute betroffen, https://www.finet.hk/newscenter/news_content/60fe18aabde0b337360b8f5e

https://www.contractpharma.com/contents/view_breaking-news/2021-07-22/aptamer-and-wuxi-apptec-form-research-partnership/ Aptamer and WuXi AppTec Form Research Partnership http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1114692/hk-stock-news Some WUXI APPTEC (02359 HK) Directors Plan to Dump 330K Shrs

Zhongtai International: Reiterate WuXi AppTec (02359) "overweight" rating target price raised 18.5% to 203.6 Hong Kong dollars https://hk.investing.com/news/stock-market-news/article-177846

Consun Pharmaceutical (01681) und WuXi AppTec (02359) sind eine strategische Kooperation eingegangen https://wap.eastmoney.com/a/202107192002870128.html

Morgan Stanley: WuXi AppTec (2359 HK) results forecast to beat market expectations and raise target price to HK$200 https://m.jrj.com.cn/madapter/hk/2021/07/16105333106312.shtml According to a research report published by Morgan Stanley, WuXi AppTec (2359 HK)'s initial earnings for the first half of the year beat market expectations. The bank has raised the company's 2021-2024 earnings forecast by 6% to 10%, and its estimates reflect clinical testing services. And the impact of the increase in CDMO/CMO revenue, the expansion of gross profit margin and the decrease in cost-to-expense ratio, the company’s H-share target price was raised from HK$178 to HK$200, and the rating was increased. At the same time, the target under the basic scenario, the bullish and bearish scenario The price rose by 12% to 13%.